ArticlePsychopharmacology2020
Anxiolytic effects of the novel α
Article in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Therapeutic potential of combining mirogabalin with antidepressants in relieving hypersensitivity: evidence from a mouse model of neuropathic pain.Pharmacological reports : PR · 2026Article
- Place preference in a female adolescent rat model of neuropathic pain: The effects of cannabidiol and oxycodone on cerebellum cell density.Psychopharmacology · 2026Article
- Mirogabalin Eliminated Pain and Reduced Inflammation in Visceral Pain.Physiological research · 2026Article
- Prokineticin-2 Participates in Chronic Constriction Injury-Triggered Neuropathic Pain and Anxiety via Regulated by NF-κB in Nucleus Accumbens Shell in Rats.Molecular neurobiology · 2024Article
- Visualization analysis of research frontiers and trends in the treatment of sciatic nerve injury.Frontiers in neurology · 2024Review
- Mirogabalin Decreases Pain-like Behaviors by Inhibiting the Microglial/Macrophage Activation, p38MAPK Signaling, and Pronociceptive CCL2 and CCL5 Release in a Mouse Model of Neuropathic Pain.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The Evidence for Effective Inhibition ofInternational journal of molecular sciences · 2022Article
- Mirogabalin Decreases Pain-like Behaviours and Improves Opioid and Ketamine Antinociception in a Mouse Model of Neuropathic Pain.Pharmaceuticals (Basel, Switzerland) · 2022Article
- VTA-NAc glutaminergic projection involves in the regulation of pain and pain-related anxiety.Frontiers in molecular neuroscience · 2022Article
- Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence.Anesthesiology and pain medicine · 2021Review
- Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease.Asian spine journal · 2021Article
- Mirogabalin-A Novel Selective Ligand for the α2δ Calcium Channel Subunit.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Effect of Gabapentin in a Neuropathic Pain Model in Mice Overexpressing Human Wild-Type or Human Mutated Torsin A.Life (Basel, Switzerland) · 2021Article
- Mirogabalin: could it be the next generation gabapentin or pregabalin?The Korean journal of pain · 2021Review
- Orofacial Neuropathic Pain-Basic Research and Their Clinical Relevancies.Frontiers in molecular neuroscience · 2021Review
- Sex Differences in a Rat Model of Peripheral Neuropathic Pain and Associated Levels of Endogenous Cannabinoid Ligands.Frontiers in pain research (Lausanne, Switzerland) · 2021Article
- Paeoniflorin attenuates chronic constriction injury-induced neuropathic pain by suppressing spinal NLRP3 inflammasome activation.Inflammopharmacology · 2020Article
- [Effects of different materials for partial sciatic nerve ligation on glial cell activation in rat models of chronic constriction injury].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Emerging roles for α2δ subunits in calcium channel function and synaptic connectivity.Current opinion in neurobiology · 2020Review
- Anxiolytic-like effects of mirogabalin, a novel ligand for αPharmacological reports : PR · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationalePsychiatric disorders such as anxiety and depression are frequently observed in neuropathic pain patients, and negatively impact their quality of life. Mirogabalin is a novel ligand for the α
objectivesTo provide further information on the pharmacological profile of mirogabalin and its utility for chronic pain therapy, we investigated its anxiolytic effects in an experimental animal model for neuropathic pain.
methodsIn chronic constriction injury (CCI) model rats, mechanical hypersensitivity was determined by the von Frey test. Anxiety- and depression-related behaviours were evaluated using the elevated plus maze test and forced swimming test, respectively.
resultsCCI model rats showed sustained tactile allodynia followed by anxiety-related behaviours, not depression-related behaviours. The tactile allodynia (significant decreases in paw withdrawal threshold) developed within 2 weeks after model preparation, whereas the anxiety-related behaviours (significant decreases in the number of entries and time spent in open arms and significant increases in time spent in closed arms) were observed at 5 weeks but not 4 weeks after model preparation. Single oral administration of mirogabalin (3 or 10 mg/kg) dose-dependently alleviated the above-mentioned anxiety-related behaviours and tactile allodynia.
conclusionsCCI model rats showed anxiety-related behaviours in a time-dependent manner in the elevated plus maze test. Mirogabalin alleviated both the anxiety-related behaviours and tactile allodynia in CCI model rats. Mirogabalin may provide effective anxiety relief as well as pain relief in patients with neuropathic pain.
Indexed as
Identifiers
31515584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.